Stay updated with breaking news from Repligen Corp. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Repligen Co. (NASDAQ:RGEN – Get Rating) – Stock analysts at William Blair lifted their Q1 2023 earnings per share estimates for Repligen in a research note issued to investors on Wednesday, April 12th. William Blair analyst M. Larew now expects that the biotechnology company will earn $0.72 per share for the quarter, up from their […]
Repligen Co. (NASDAQ:RGEN – Get Rating) shares traded up 4.3% during mid-day trading on Wednesday . The stock traded as high as $178.26 and last traded at $177.66. 322,077 shares changed hands during mid-day trading, a decline of 41% from the average session volume of 547,335 shares. The stock had previously closed at $170.39. Analysts […]
Repligen (NASDAQ:RGEN – Get Rating) and Molecular Partners (NASDAQ:MOLN – Get Rating) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation. Institutional and Insider Ownership 91.0% of Repligen shares are held by […]
Shares of Repligen Co. (NASDAQ:RGEN – Get Rating) have received a consensus rating of “Moderate Buy” from the ten brokerages that are covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and six have assigned a buy recommendation to the […]
Repligen Co. (NASDAQ:RGEN – Get Rating) has earned a consensus rating of “Moderate Buy” from the ten brokerages that are currently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the company. The average […]